Modulation of specificity protein 1 by mithramycin A as a novel therapeutic strategy for cervical cancer

Citations Over TimeTop 10% of 2014 papers

Abstract

Cervical cancer is the third most common cancer and the third leading cause of death among women. However, the standard treatment for cervical cancer includes cisplatin, which can cause side effects such as hematological damage or renal toxicity. New innovations in cervical cancer treatment focus on developing more effective and better-tolerated therapies such as Sp1-targeting drugs. Previous studies suggested that mithramycin A (Mith) inhibits the growth of various cancers by decreasing Sp1 protein. However, how Sp1 protein is decreased by Mith is not clear. Few studies have investigated the regulation of Sp1 protein by proteasome-dependent degradation as a possible control mechanism for the regulation of Sp1 in cancer cells. Here, we show that Mith decreased Sp1 protein by inducing proteasome-dependent degradation, thereby suppressing cervical cancer growth through a DR5/caspase-8/Bid signaling pathway. We found that prolonged Mith treatment was well tolerated after systemic administration to mice carrying cervical cancer cells. Reduction of body weight was minimal, indicating that Mith was a good therapeutic candidate for treatment of cancers in which Sp1 is involved in promoting and developing disease.

Related Papers

• → Proteasomal and lysosomal protein degradation and heart disease(2013)165 cited
• → Regulation of Protein Degradation by Proteasomes in Cancer(2018)106 cited
• → The Proteasome-associated Protein Ecm29 Inhibits Proteasomal ATPase Activity and in Vivo Protein Degradation by the Proteasome(2013)53 cited
• → Protein Degradation by the 26S Proteasome System in the Normal and Stressed Myocardium(2006)38 cited
• Ubiquitin-like Protein FAT10-mediated Proteasome Degradation(2014)